This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

United States Immunology Drugs Market Report 2018-2024 - ResearchAndMarkets.com

February 27, 2019

DUBLIN--(BUSINESS WIRE)--Feb 27, 2019--The “Immunology Drugs Market Report Suite for the United States - 2018-2024” report has been added to ResearchAndMarkets.com’s offering.

The United States immunology drugs report provides market analysis, sizing, forecasts, dosage units sold, average selling prices, and market shares of the immunology drugs within 5 major diseases.

The report analyses key factors instrumental in changing the market scenario and provides a forecast of the future immunology market in the United States. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.

The U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost-effective drugs in treating these diseases, there is also an increased number of drugs in development for the same. Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. This report covers second-line treatments, their dosage, comparative cost studies, market size and revenue forecasts.

Key Topics Covered:

1 Executive Summary

  • Market Overview
  • Competitive Landscape
  • Market Trends
  • Key Market Developments
  • Markets Included
  • Version History
  • 9-Step Methodology

2 Mechanism Of Action

2.1 Introduction

2.1.1 Tumor Necrosis Factor (Tnf)

2.1.2 B-Cell Inhibitors

2.1.3 Interleukin Inhibitors

2.1.4 Janus Kinase Inhibitors

2.1.5 Co-Stimulation Modulators

3 Product Assessment

3.1 Key Marketed Products

3.1.1 Abatacept (Orencia) Future Developments Currently Marketed Products By Company

3.1.2 Adalimumab (Humira)

3.1.3 Certolizumab Pegol (Cimzia)

3.1.4 Etanercept (Enbrel, Benepali)

3.1.5 Golimumab (Simponi)

3.1.6 Infliximab (Remicade, Inflectra, Remsima, Flixabi, Renflexis)

3.1.7 Natalizumab (Tysabri)

3.1.8 Rituximab (Rituxan, Mabthera, Rixathon, Truxima)

3.1.9 Tocilizumab (Actemra/Roactemra)

3.1.10 Tofacitinib (Xeljanz)

3.1.11 Ustekinumab (Stelara)

3.1.12 Vedolizumab (Entyvio)

3.2 Key Products In Pipeline

3.2.1 Barcitinb (Olumiant)

3.2.2 Guselkumab (Tremfya)

3.2.3 Cobitolimod (Kappaproct)

3.2.4 Mavrilimumab

3.2.5 Sirukumab

3.2.6 Vobarilizumab

3.3 Products In Development By Core Companies

3.4 Clinical Trial By Disease

3.4.1 Rheumatoid Arthritis Study Completion Date: 2017 Study Completion Date: 2016 803.4.2 Crohn’s Disease (Cd) Study Completion Date: 2017 Study Completion Date: 2016 Study Completion Date: 2015

3.4.3 Ankylosing Spondylitis (As) Study Completion Date: 2017 Study Completion Date: 2016 Study Completion Date: 2015

3.4.4 Psoriasis (Ps) Study Completion Date: 2017 Study Completion Date: 2016

3.4.5 Ulcerative Colitis (Uc) Study Completion Date: 2016 Study Completion Date: 2015

4 United States Immunology Market Overview

4.1 Introduction

4.2 Market Overview

4.3 Market Share Analysis

4.4 Drivers And Limiters

4.4.1 Market Drivers

4.4.2 Market Limiters

4.5 Competitive Analysis

5 Country Profile

5.1 United States

5.1.1 Population And Demographics

5.1.2 Prevalence Of Immunology Diseases

5.1.3 Drug Cost Analysis

5.1.4 Annual Drug Cost Analysis

5.1.5 Disease Treatment Population Size

5.1.6 Units Of Drugs Sold

6 Rheumatoid Arthritis Market

6.1 Introduction

6.1.1 Causes And Disease Progression

6.1.2 Diagnosis And Treatment Options

6.1.3 Symptoms And Complications

6.1.4 Epidemiology

6.2 Market Overview

6.3 Market Share Analysis

7 Crohn’s Disease Market

7.1 Introduction

7.1.1 Causes And Disease Progression

7.1.2 Diagnosis And Treatment Options

7.1.3 Symptoms And Complications

7.1.4 Epidemiology

7.2 Market Overview

7.3 Trend Analysis

8 Ankylosing Spondylitis Market

8.1 Introduction

8.1.1 Causes And Disease Progression

8.1.2 Diagnosis And Treatment Options

8.1.3 Symptoms And Complications

8.1.4 Epidemiology

8.2 Market Overview

8.3 Trend Analysis

9 Psoriasis Market

9.1 Introduction

9.1.1 Causes And Disease Progression

9.1.2 Diagnosis And Treatment Options

9.1.3 Symptoms And Complications

9.1.4 Epidemiology

9.2 Market Overview

9.3 Trend Analysis

10 Ulcerative Colitis Market

10.1 Introduction

10.1.1 Causes And Disease Progression

10.1.2 Diagnosis And Treatment Options

10.1.3 Symptoms And Complications

10.1.4 Epidemiology

10.2 Market Overview

10.3 Trend Analysis

11 Company Profiles

11.1 Abbvie Inc.

11.1.1 Business Overview

11.1.2 Financials

11.1.3 Swot Analysis Strengths Weakness Opportunity Threats

11.2 Amgen Inc.

11.3 Biogen Idec

11.4 Bristol-Myers Squibb

11.5 Hoffmann-La Roche Ltd

11.6 Johnson & Johnson/Janssen

11.7 Novartis Ag

11.8 Pfizer Inc.

11.9 Takeda Pharmaceutical Company Limited

11.10 Ucb S.A.

12 Abbreviations

13 Appendix: Company Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/n5d49s/united_states?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190227005319/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/27/2019 04:41 AM/DISC: 02/27/2019 04:41 AM